In accordance with this hypothesis, we observed a significantly reduced vascular area in the tumor periphery of TP53‐mutant HBCx‐14 but not TP53 wt HBCx‐90 tumors at 1 week after the end of combined therapy (d21, Fig 7A and B). This evidence concerns the gene TP53 and neoplasm.